Slide 1: Q2 2025 Business Update
Nasdaq: PAVM Q2 2025 Business Update August 14, 2025 LISHAN AKLOG, MD Chairman & CEO DENNIS MCGRATH President & CFO
Slide 2: Disclaimer
Disclaimer ▪ This presentation may contain certain forward-looking statements related to PAVmed Inc. or Lucid Diagnostics Inc. (the “Companies”) that involve risks and uncertainties. ▪ Actual results and events may differ significantly from results and events discussed in forward- looking statements
Slide 3: Lishan Aklog, M.D. Chairman & CEO
Nasdaq: PAVM Lishan Aklog, M.D. Chairman & CEO
Slide 4: PAVmed Corporate Structure
PAVmed Corporate Structure Nasdaq: PAVM D I G I T A L H E A L T H M E D T E C H D IAGN OS TI CS PMX Privately Held Privately Held Digital Cancer Care Platform & Smart Incubator for MedTech Technologies, including Vascular Access Port PortIO, EsoCure, and CarpX B I O P H A R M A Nasdaq: LUCD Early De
Slide 5: Recent Highlights
Recent Highlights Lucid Diagnostics ▪ 2Q25 EsoGuard revenue $1.2M, 1Q25 test volume 2,756 ▪ MolDX Contractor Advisory Committee (CAC) Meeting scheduled for September 4 ▪ Partnered with Hoag to launch comprehensive EsoGuard esophageal precancer testing program ▪ Strengthened balance sheet with underw
Slide 6: Recent Highlights
Recent Highlights Veris Health ▪ Completed $2.5 million direct equity financing, supplementing previous $2.4 million financing at a $35 million pre-money valuation ▪ Successfully restarted development of implantable physiological monitor after completing private placement financing; reengaged with F
Slide 7: Q2 2025 Financial Update
Nasdaq: PAVM Q2 2025 Financial Update
Slide 8: Balance Sheet
Balance Sheet ($ in thousands) 2Q25 1Q25 Change Assets Cash $4,004 $2,700 $1,304 Equity Method Investments (Lucid) $35,998 $46,641 $(10,643) All other Assets $3,891 $3,482 $409 Liabilities Accounts Payable $387 $369 $18 Senior Secured Convertible Notes $6,800 $6,600 $200 Other Current Liabilities $3
Slide 9: P&L
P&L ($ in thousands) 2Q25 2Q24 Change 2Q25 - YTD 2Q24 - YTD Change Revenue + Management Fee Income $3,156 $3,479 $(323) $6,314 $6,989 $(675) Operating Expenses $4,721 $14,663 $(9,942) $10,174 $29,711 $(19,537) Net Income (Loss) $(12,324) $(14,914) $2,590 $6,300 $(33,426) $39,726 EBITDA $(11,903) $(1
Slide 10: Non-GAAP Operating Expense
Non-GAAP Operating Expense To supplement our unaudited financial results presented in accordance with U.S. generally accepted accounting principles (GAAP), management provides certain non-GAAP financial measures of the Company’s financial results. Non-GAAP financial measures are presented with the i
Slide 11: Q&A
XK PAVmed Nasdaq: PAVM aty Q&A
Slide 12: Closing Remarks
Nasdaq: PAVM Closing Remarks